A lipase mutant and a method for preparing ascorbyl tetraisopalmitate using the same
By mutation of lipase, a lipase mutant with efficient catalytic activity was obtained, which solved the problem of low catalytic efficiency in the production of ascorbic acid tetraisopalmitate in the prior art, and achieved the preparation of high-purity products, which was in line with green and safe Production requirements.
Patent Information
- Application Number
- CN202410462150.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-17
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2044-04-17
AI Technical Summary
In the prior art, the production process of ascorbic acid tetraisopalmitate has problems such as low catalytic efficiency, high by-product content and difficult to separate. Especially in the catalytic synthesis method of biological enzymes, the catalytic efficiency of Novozym 435 lipase is not high, which is difficult to Realize industrial production.
By mutation of lipase, specifically, the 188th asparagine of wild-type lipase is mutated to glutamate and phenylalanine at 242nd to proline, a highly catalytically active lipase mutant is obtained. This mutant is used to catalyze the synthesis of ascorbic acid tetraisopalmitate in an organic medium, and a high-purity product is obtained through simple operations such as filtration centrifugation and organic extraction.
The catalytic efficiency is improved, the substrate conversion rate can reach more than 99%, the conditions are mild, the process is simple to operate, and the pollution is small, and it conforms to the green and safe production concept. The product is suitable for use in medicine and cosmetics.
Smart Images

Figure CN118421599B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biological enzyme catalysis, and particularly relates to a lipase mutant and a method for preparing ascorbic acid tetraisopalmitate by using the lipase mutant. Background Art
[0002] Ascorbyl Tetraisopalmitate (VC-IP) is an oil-soluble vitamin C (VC, L-ascorbic acid) derivative. The molecular structure of VC contains a diol structure, which easily releases H atoms and has strong reducing properties. It can be used as a nutritional supplement and antioxidant. VC-IP is formed by replacing the hydroxyl groups at positions 2, 3, 5, and 6 on VC with isopalmitoyl residues, which increases the lipophilic properties and allows it to be directly absorbed by the skin and enter the cells more smoothly. VC-IP is converted into VC through the enzymatic reaction of esterase, exerting an antioxidant effect, making up for the shortcoming of VC's poor ability to penetrate the skin as a water-soluble antioxidant.
[0003]
[0004] Vitamin C (VC, L-ascorbic acid)
[0005] In addition, foreign researchers have conducted a number of safety tests on VC-IP, including human sensitization tests, closed patch tests, eye irritation tests, mutation tests, and all of them were negative, indicating that VC-IP itself has almost no possibility of tissue damage or carcinogenicity. It is often used as an antioxidant and skin moisturizer in the field of daily chemicals. VC-IP inhibits intracellular tyrosinase activity and melanin production. VC is easily affected by light, heat, oxygen, moisture, pH, metal ions, ultraviolet rays, etc., which significantly reduce its potency. Esterification modification of VC to convert L-ascorbic acid into its derivative form can improve its stability, solve its poor oil solubility problem, and increase its Surface activity and so on make it a new type of additive with both antioxidant and emulsifying properties. The application prospects of ascorbyl tetraisopalmitate in the fields of medicine, feed, food, etc. have attracted increasing attention, so it has high research value and broad development prospects.
[0006] According to the literature, there are two main production processes for VC-IP: chemical synthesis and enzyme-catalyzed synthesis. There are two main chemical synthesis methods: (1) 2-hexyldecanoic acid and a chlorination agent are reacted to generate 2-hexyldecanoyl chloride, which is then reacted with VC to generate VC-IP; (2) VC and 2-hexyldecanoic acid are subjected to an esterification reaction in an organic medium solvent in the presence of an alkaline substance and a condensing agent to obtain VC-IP. In the synthesis of ascorbyl tetraisopalmitate by chemical synthesis, many reagents are used, the feed amount is high, the reaction control is complex, a large amount of waste liquid and wastewater is generated, industrial production is difficult, and the process control is strict, which is not conducive to large-scale industrial production. The enzyme-catalyzed synthesis method generally uses the commercial Novozym 435 lipase to catalyze the substrate hydrolysis and ester exchange under specific conditions to synthesize VC-IP. Its catalytic efficiency is low, the by-product content is high, and it is difficult to separate, which is not conducive to industrial production.
[0007] Therefore, there is an urgent need to provide a lipase with high catalytic activity, which can improve the catalytic efficiency and prepare high-purity ascorbyl tetraisopalmitate. Summary of the invention
[0008] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a lipase mutant and a method for preparing ascorbyl tetraisopalmitate using the same. The lipase mutant provided by the present invention has high-efficiency catalytic activity, can improve catalytic efficiency, and prepare high-purity ascorbyl tetraisopalmitate.
[0009] The present invention provides a lipase mutant.
[0010] Specifically, a lipase mutant, the amino acid sequence of the lipase mutant is shown in SEQ ID NO.1.
[0011] The lipase mutant is obtained by mutating the 188th asparagine of the wild-type lipase to glutamic acid and the 242nd phenylalanine to proline as shown in SEQ ID NO. 2. The wild-type lipase has a corresponding amino acid sequence length of 295aa and a protein molecular weight of about 31.4kDa.
[0012] SEQ ID NO.1:MFARELGIAAALGLLAQAAPAPIERRAVSTALLDKMEL FSQYSAAAYCSSNINSASTALSCSTDNCPLVVSAAPTVLDEFNETAEFGDTAGFIAVDATNKAIIVSFRGSHDLSNWIANIDFGLTDASSICSGCEIHSGFWKAWETVASTITAKIEAALTSHADYEL VFTGHSLGAALAAVAATVLREDGYTVDLNFGQPRIGNLALADYITNQNKGSNYRVTHEDDIVPKLPPKLLGYHHPSPEYWITSDSGVTVTTSDITEVVGVDSKSGNDGTLLDSVSAHRYYFGYISKCS.
[0013] SEQ ID NO.2: MFARELGIAAALGLLAQAAPAPIERRAVSTALLDKMEL FSQYSAAAYCSSNINSASTALSCSTDNCPLVVSAAPTVLDEFNETAEFGDTAGFIAVDATNKAIIVSFRGSHDLSNWIANIDFGLTDASSICSGCEIHSGFWKAWETVASTITAKIEAALTSHADYEL VFTGHSLGAALAAVAATVLRNDGYTVDLNFGQPRIGNLALADYITNQNKGSNYRVTHEDDIVPKLPPKLLGYHHFSPEYWITSDSGVTVTTSDITEVVGVDSKSGNDGTLLDSVSAHRYYFGYISKCS.
[0014] In some embodiments of the present invention, the nucleotide sequence of the wild-type lipase is shown in SEQ ID NO.3, which has a length of 888 bp. The nucleotide sequence encoding the wild-type lipase obtained after codon optimization is shown in SEQ ID NO.4.
[0015] SEQ ID NO.3:5’-ATGCTTTTCGCCCGAGAACTAGGGATTGCAGCGG CTTTGGGCTTGTTAGCCCAGGCTGCTCCTGCGCCGATCGAACGTCGAGCTGTCTCCACTGCCTTGCTGGACAAGATGGAGCTCTTCTCCCAGTACAGCGCGGCCGCCTATTGCTCTTCGAACATCAATTCGGCGAGCACCGCGCTGTCCTGCTCCACAGACAACTGCCCCTTGGTCGTGTCTGCGGCTCCCACCGTTCTCGACGAGTTCAACGAAACCGCCGAGTTCGGTGATACAGCCGGCTTCATTGCTGTCGACGCAACCAACAAGGCCATCATTGTCTCCTTCCGTGGCAGCCATGACCT CTCCAACTGGATCGCCAACATAGACTTTGGCCTCACCGACGCCAGCAGCATCTGCAGTGGCTGTGAAATCCACAGTGGGTTCTGGAAGGCCTGGGAGACGGTCGCCAGCACCATCACGGCCAAGATCGAGGCTGCCCTTACCAGCCACGCGGACTACGAGCTTGTCTTCACCGGCCACAGCCTGGGCGCCGCCCTGGCAGCAGTCGCAGCCACCGTGCTCCGCAACGACGGCTACACAGTTGACCTGAACTTCGGCCAACCGCGGATCGGCAACCTCGCTCTGGCCGACTACATCACCAACCAGAACAAGGGCAGCAACTACCGGGTCACGCACGAGGACGACATCGTTCCCAAGCTCCCTCCGAAGTTGCTGGGATACCACCACTTCAGCCCGGAGTACTGGATCACCAGCGACAGCGGCGTGACCGTCACTACCTCGGACATCACTGAGGTGGTGGGCGTGGACTCCAAGTCCGGCAACGACGGGACCCTGCTCGACAGCGTCTCTGCCCACAGATACTACTTTGGCTACATCAGCAAGTGTTCGTGA-3’。
[0016] SEQ ID NO.4: 5’-ATGTTCGCGCGTGAGCTGGGTATCGCGGCGGCGC TGGGCCTGCTGGCGCAGGCGGCGCCGGCGCCGATCGAACGTCGTGCGGTTAGCACCGCGCTGCTGGATAAAATGGAACTGTTCAGCCAGTACAGCGCGGCGGCGTACTGCAGTAGCAACATCAACAGCGCGAGCACCGCGCTGAGCTGCAGCACCGATAACTGCCCGCTGGTTGTTAGCGCGGCGCCGACCGTTCTGGATGAATTTAACGAAACCGCGGAGTTCGGCGATACCGCGGGTTTCATCGCGGTTGATGCGACCAACAAAGCGATCATTGTTAGCTTCCGTGGCAGCCACGATCTGTCAAACTGGATCGCGAACATCGACTTCGGCCTGACCGACGCGAGCAGCATCTGCTCTGGTTGCGAAATCCACAGCGGTTTCTGGAAAGCGTGGGAAACCGTTGCGTCCACCATCACCGCGAAAATCGAAGCGGCGCTGACCTCCCACGCGGATTACGAACTGGTTTTTACCGGCCACAGCCTGGGTGCGGCGCTGGCGGCG GTTGCGGCGACCGTTCTGCGTAACGATGGTTACACCGTTGATCTGAACTTCGGCCAGCCGCGTATCGGTAACCTGGCGCTGGCGGATTATATTACCAACCAGAACAAAGGCAGCAACTATCGTGTTACTCACGAAGATGATATTGTGCCAAAACTGCCGCCTAAACTGCTGGGCTATCACCATTTTTCTCCGGAATATTGGATCACTAGCGACTCCGGCGTTACCGTTACCACCTCTGATATCACCGAAGTTGTTGGTGTTGACTCTAAAAGCGGTAACGATGGTACCCTGCTGGATTCTGTTTCTGCGCACCGTTACTACTTCGGCTACATTAGCAAATGCAGCTAA-3’。
[0017] In some embodiments of the present invention, the lipase mutant is derived from Aspergillus homomorphus.
[0018] The present invention also provides a nucleic acid molecule, which encodes the lipase mutant.
[0019] Preferably, the nucleotide sequence of the nucleic acid molecule is as shown in SEQ ID NO.5.
[0020] SEQ ID NO.5: 5’-ATGTTTGCGCGTGAACTGGGTATTGCCGCTGCAC TGGGCCTGCTGGCGCAAGCGGCTCCGGCCCCGATCGAACGTCGTGCTGTGTCTACTGCTCTGCTGGATAAAATGGAACTGTTCTCTCAGTACTCTGCAGCCGCGTACTGTAGCTCCAACATCAACTCCGCATCTACCGCGCTGAGCTGCAGCACGGATAATTGCCCGCTGGTTGTTTCCGCTGCTCCGACTGTGCTGGACGAGTTCAACGAAACTGCGGAATTCGGCGACACCGCAGGTTTCATTGCTGTAGACGCAACGAACAAAGCCATTATCGTGTCCTTTCGTGGTTCCCACGACCTGTCCAACTGGATCGCTAACATTGATTTCGGTCTGACCGACGCTTCTTCCATTTGCTCCGGTTGCGAGATTCACTCCGGTTTTTGGAAAGCCTGGGAAACCGTAGCCTCCACTATCACTGCAAAAATCGAGGCGGCACTGACTTCTCACGCGGACTACGAACTGGTATTTACTGGTCACTCTCTGGGTGCTGCTCTGGCAGCAGTTGCGGCTACCGTACTGCGCGAGGATGGTTACACGGTTGACCTGAACTTCGGCC AGCCACGTATCGGTAATCTGGCACTGGCAGACTACATCACCAACCAGAACAAGGGTTCCAATTACCGTGTGACGCATGAAGATGATATCGTCCCGAAGCTGCCGCCGAAACTGCTGGGTTACCATCACCCTAGCCCGGAATATTGGATTACTAGCGATAGCGGTGTAACCGTGACCACGTCCGATATCACCGAAGTTGTAGGCGTTGATTCTAAGTCCGGCAACGACGGCACCCTGCTGGACTCTGTAAGCGCTCACCGCTACTACTTCGGTTACATCAGCAAATGTTCTTAA-3’。
[0021] The present invention also provides a recombinant expression vector, which comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.5.
[0022] The present invention also provides a recombinant engineered bacterium, wherein the recombinant engineered bacterium comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.5 or the above-mentioned recombinant expression vector.
[0023] In some embodiments of the present invention, the recombinant engineered bacteria include bacterial or fungal cells.
[0024] In some embodiments of the present invention, the engineered bacteria is Escherichia coli.
[0025] The present invention also provides a method for preparing the lipase mutant.
[0026] Specifically, the method for preparing the above lipase mutant comprises the following steps:
[0027] (1) cultivating the above-mentioned recombinant engineered bacteria;
[0028] (2) Inducing the recombinant engineered bacteria to express a lipase mutant.
[0029] More specifically, the method for preparing the above lipase mutant comprises the following steps:
[0030] (1) Introducing NdeI and XhoI sites at both ends of the nucleic acid molecule with a nucleotide sequence as shown in SEQ ID NO.5, respectively, and cloning it into a pET28a vector to obtain a recombinant vector; the constructed recombinant vector is transformed into Escherichia coli BL21 (DE3) competent cells by a chemical transformation method, and spread on an LB plate containing kanamycin resistance. After culturing, a single clone cell is picked to obtain a recombinant genetically engineered bacterium;
[0031] (2) Inducing the expression of the recombinant genetically engineered bacteria to obtain an enzyme solution containing the lipase mutant.
[0032] During the induction expression process, lipase is expressed by intracellular metabolism to obtain wet bacteria, which can be further broken down to obtain a clear liquid.
[0033] Preferably, in step (2), the cell concentration of the wet cells is 95 g / L to 140 g / L.
[0034] Preferably, in step (2), the step of immobilizing the lipase is also included to obtain immobilized lipase. The immobilization treatment can further improve the lipase activity.
[0035] Specifically, the immobilization steps are as follows: take the wet bacteria or the clear liquid after cell wall breaking, dilute to a bacteria concentration of 30-80 g / L to obtain a diluted solution; then adjust the pH to 7.0-8.0, and then adjust the pH to 6.0-6.5, slowly add chitosan solution under stirring conditions until flocculated solids are precipitated, add diatomaceous earth to adsorb the flocculated solids, let stand, separate the solid and liquid to obtain a precipitate, dry, and obtain immobilized lipase.
[0036] Preferably, the added amount (g) of the diatomaceous earth is 10 w / V% to 30 w / V% of the volume (L) of the dilution liquid.
[0037] The invention also provides a method for synthesizing ascorbyl tetraisopalmitate.
[0038] Specifically, a method for synthesizing ascorbyl tetraisopalmitate utilizes the above-mentioned lipase mutant to synthesize ascorbyl tetraisopalmitate.
[0039] Preferably, the synthesis method comprises the following steps: using ascorbic acid as a substrate, 2-n-hexyldecanoic acid as a co-substrate, and an organic solvent as a reaction medium, reacting under the catalytic action of the above-mentioned lipase mutant to synthesize ascorbyl tetraisopalmitate.
[0040] Preferably, the final concentration of ascorbic acid added is 0.10-0.20 mol / L.
[0041] Preferably, the final molar ratio of the ascorbic acid to the 2-n-hexyldecanoic acid is 1:(4-12); further preferably, the final molar ratio of the ascorbic acid to the 2-n-hexyldecanoic acid is 1:(6-8).
[0042] Preferably, the lipase mutant is added in the form of immobilized lipase, and the amount of the immobilized lipase added is 20-80 g / L; further preferably, the amount of the immobilized lipase added is 20-60 g / L, such as 30 g / L, 40 g / L, 50 g / L.
[0043] Preferably, the 2-n-hexyldecanoic acid is added by feeding, and the speed of the feeding is controlled to be 5ml / L~60mL / L; further preferably, the flow rate is controlled to be 5ml / L~40mL / L; more preferably, the flow rate is controlled to be 10ml / L~30mL / L.
[0044] Preferably, in the reaction system, the water content in the reaction system is ≤4%; further preferably, the water content in the reaction system is 0.2% to 1%. The water content of the system is measured using a Swiss Metrohm 831KF Karl Fischer moisture analyzer, and a water absorbent such as anhydrous sodium sulfate, anhydrous calcium chloride, 5A molecular sieve, fungus powder, etc. can be added during the reaction, preferably anhydrous sodium sulfate, fungus powder, etc.
[0045] Preferably, the organic solvent includes N,N-dimethylformamide. N,N-dimethylformamide plays a solubilizing role in the reaction, and can increase the solubility of Na2SO3 and 2-n-hexyldecanoic acid in the co-substrate solution in the reaction solution, which is beneficial to improve the reaction efficiency.
[0046] Preferably, the organic solvent further comprises at least one of tert-butanol, tert-amyl alcohol, acetone, petroleum ether and n-hexane; further preferably, the organic solvent further comprises at least one of tert-butanol, tert-amyl alcohol, petroleum ether and n-hexane.
[0047] Preferably, the reaction temperature is 0°C to 80°C; further preferably, the reaction temperature is 20°C to 60°C; more preferably, the reaction temperature is 45°C to 50°C.
[0048] The lipase mutant obtained by screening in the present invention has strong substrate-specific recognition and binding capabilities in VC esterification reactions, has high catalytic activity for C14-C18 saturated organic acids (esters), can improve catalytic efficiency, and prepare high-purity ascorbic acid tetraisopalmitate.
[0049] Compared with the prior art, the present invention has the following beneficial effects:
[0050] (1) The lipase mutant provided by the present invention is obtained by mutating the asparagine at position 188 to glutamic acid and the phenylalanine at position 242 to proline in the amino acid sequence of the wild-type lipase. The lipase mutant provided by the present invention is used as a catalyst to synthesize L-ascorbic acid tetraisopalmitate in an organic medium reaction system, and a high-purity product can be obtained by simple operations such as filtration, centrifugation, and organic extraction; and the final substrate conversion rate can reach more than 99%, and the catalytic efficiency of the lipase mutant is about 1.5 times that of the wild-type lipase.
[0051] (2) The lipase mutant provided by the present invention is used to synthesize ascorbyl tetraisopalmitate, and the conditions are mild, the process operation is simple, the pollution is small, it is green and safe, and the product has high purity, which conforms to the "green and safe" production concept. The product is suitable for use in pharmaceutical raw materials and cosmetic active ingredient addition. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 It is the SDS-PAGE gel image of wild-type lipase LP and its mutant LP-N188E / F242P;
[0053] Figure 2 The absorbance working curve of oleic acid in Example 4 is shown;
[0054] Figure 3 This is the HPLC chart of 2-n-hexyldecanoic acid sampled and tested during the reaction of 10 hours in Example 5;
[0055] Figure 4 This is the HPLC chart of sampling and detecting VC-IP after the reaction in Example 5;
[0056] Figure 5 This is a result diagram of exploring the best reaction medium for lipase-catalyzed synthesis of VCIP in Example 6;
[0057] Figure 6 This is a result diagram of the optimal co-substrate flow acceleration for the lipase-catalyzed synthesis of VCIP in Example 6;
[0058] Figure 7 This is a result diagram of exploring the optimum reaction temperature for lipase-catalyzed synthesis of VCIP in Example 6;
[0059] Figure 8 This is a graph showing the results of exploring the optimal final molar ratio of substrate to cosubstrate for the lipase-catalyzed synthesis of VCIP in Example 6. DETAILED DESCRIPTION
[0060] In order to make the technical scheme of the present invention more clearly understood by those skilled in the art, the following embodiments are listed for illustration. It should be pointed out that the following embodiments do not limit the protection scope of the present invention.
[0061] Unless otherwise specified, the raw materials, reagents or devices used in the following examples can be obtained from conventional commercial sources or by existing known methods.
[0062] Example 1: Culture medium and reagent configuration
[0063] LB medium: 10 g / L tryptone, 5 g / L yeast extract, 10 g / L NaCl, dissolved in purified water, adjust pH to 7.0-7.2 with 1 M NaOH; autoclave at 121°C for 21 min, store at 4°C.
[0064] TB medium: 12 g / L peptone, 24 g / L yeast extract, 10 ml glycerol, 2.31 g / L KH2PO4, 12.54 g / L K2HPO4, dissolved in purified water, adjust pH to 7.0-7.2 with 1 M NaOH; autoclave at 121°C for 21 min, store at 4°C.
[0065] Glacial acetic acid solution: Measure 1.5 mL of glacial acetic acid (AR), add purified water to make up to 100 mL, and refrigerate at 4°C until use.
[0066] Chitosan carrier solution: weigh 2.6 g chitosan, add 4-8 mL glacial acetic acid solution, stir and grind until it becomes a gel, then add glacial acetic acid solution to 100 mL, stir and dissolve, and refrigerate at 4°C for use.
[0067] CaCl2 solution: Weigh 20 g of anhydrous CaCl2 (AR), dissolve it in purified water and make up to 100 mL, then refrigerate at 4°C until use.
[0068] NaOH solution: 0.5 mol / L NaOH solution, weigh 2 g NaOH(AR), dissolve it in purified water and make up to 100 mL, refrigerate at 4°C until use.
[0069] Example 2: Obtaining lipase encoding genes and their mutants
[0070] The wild-type lipase provided by the present invention has a coding sequence derived from Aspergillus humomorphus (NCBI reference sequence: NW_020291929.1), and its nucleotide sequence is shown in SEQ ID NO: 3, and the corresponding amino acid sequence is shown in SEQ ID NO: 2. The nucleotide sequence encoding the wild-type lipase obtained after codon optimization is shown in SEQ ID NO: 4.
[0071] The lipase mutants were obtained by using error-prone PCR and site-directed saturation mutagenesis techniques. The SEQ ID NO:4 lipase gene was mutated using error-prone PCR techniques. The PCR products were purified, digested, and connected to the pET28a vector. The obtained mutant plasmids were chemically transformed into competent cells of Escherichia coli BL21 (DE3). The obtained strains were cultured, and an enzyme activity determination method was established. The dominant mutants were screened, sequenced, and preserved to obtain the mutation site information. The selected mutation sites were subjected to site-directed saturation mutagenesis and multi-site combined mutagenesis using the whole plasmid PCR method to obtain mutant strains. After the mutant strains were cultured, the dominant mutants were further screened, and the dominant mutants were sequenced, verified, and preserved. Table 1 shows the comparison results of the enzyme activity effects of the various mutant strains.
[0072] Table 1 Comparison of enzyme activity effects of mutants
[0073]
[0074]
[0075] In the above experiment, the enzyme activity detection method is as described in Example 4. Enzyme activity effect evaluation: The average value of mutant enzyme activity / wild-type enzyme activity is 100% to 120%, marked as +; 120% to 140%, marked as ++; 140% to 160%, marked as +++.
[0076] As shown in Table 1, the enzyme activity of the lipase mutant with the amino acid sequence of SEQ ID NO.1 is about 1.5 times that of the wild-type lipase (SEQ ID NO.2).
[0077] Example 3: Construction of E. coli BL21(DE3) / pET28a-LP-N188E / F242P engineered bacteria and preparation of crude enzyme solution
[0078] 1. Construction of engineered bacteria
[0079] Construction of genetically engineered bacteria: The LP-N188E / F242P encoding gene was inserted between the NdeI and XhoI restriction enzyme sites on the plasmid pET28a vector to obtain the recombinant plasmid pET28a-LP-N188E / F242P. The recombinant plasmid was introduced into the competent cell E.coli BL21 (DE3) to obtain the engineered bacteria E.coli BL21 (DE3) / pET28a-LP-N188E / F242P. The plasmid was extracted and sequenced from the engineered bacteria, indicating that each gene was correctly inserted. The nucleotide sequence of the LP-N188E / F242P encoding gene is shown in SEQ ID NO:5.
[0080] 2. Preparation of wet cells of engineered bacteria
[0081] Wet cells were prepared as follows: the engineered bacteria E. coli BL21 (DE3) / pET24a-Beri-LP-N188E / F242P was inoculated into LB liquid medium containing kanamycin at a final concentration of 100 μg / mL, and cultured at 37 ° C, 160 rpm for 8-12 hours, and then transferred to TB liquid medium containing 100 μg / mL kanamycin at a volume concentration of 2% inoculation, and cultured at 37 ° C, 160 rpm until the cell concentration OD600 reached 4.0-6.0, and IPTG was added to the culture at a final concentration of 0.3 mM, and induced at 26 ° C for 8 hours to obtain an induced culture solution. Under the same conditions, the culture solution without IPTG was used as the uninduced control culture solution. The culture solution was then centrifuged at 4°C and 6000rpm for 15min, and the supernatant was discarded; the bacteria were then resuspended in 50mM Tris-HCl buffer at pH 7.0, centrifuged at 4°C and 6000rpm for 15min, and the supernatant was discarded to collect the wet bacteria. The wet bacteria were calculated according to the wet weight and the volume was adjusted to 200g / L with purified water. The cells were then homogenized and broken by a high-pressure homogenizer at 4°C and 600-800Bar for 3 times, and the broken cell clear liquid was collected and stored at -20°C for later use.
[0082] 3. Preparation of samples for SDS-PAGE detection:
[0083] Take 20 μL of bacterial suspension from the uninduced control culture and induced culture, add 4 μL of 6x Protein Loading Buffer, mix well, and boil for 10 minutes. After boiling, centrifuge at 12000 rpm for 1 minute, and take 15 μL of supernatant for SDS-PAGE detection. The protein marker is BluePlus Protein Marker (14-120 kDa). Figure 1 The SDS-PAGE gel image of wild-type lipase LP and its mutant LP-N188E / F242P, wherein lane M is the marker; lane 1 is the wild-type; and lane 2 is the mutant LP-N188E / F242P. Figure 1 As shown, SDS-PAGE detection showed that the genes encoding lipase LP-N188E / F242P (referred to as Beri-LP enzyme in the present invention) were successfully expressed in Escherichia coli, and the protein molecular weight was about 31 kDa, which was consistent with the expected value.
[0084] Example 4: Preparation of immobilized Beri-LP enzyme and determination of its enzyme activity
[0085] Immobilization method of lipase: dilute the cell-broken clear liquid in Example 3 to 50 g / L, first adjust the pH of the clear liquid to 7.5 with 2 mol / L NaOH solution, then adjust the pH to 6.5 with CaCl2 solution, slowly drop chitosan solution under stirring speed of 150 rpm / min until flocculated solids are precipitated, crosslinking time 2.0 h, pH 6.5, temperature 25° C. Add diatomaceous earth to adsorb flocculated solids, the amount of diatomaceous earth is: 20% (w / V%) wet weight, stand overnight, centrifuge, collect precipitates, and dry at 45° C. for standby use.
[0086] Lipase activity determination: copper soap method:
[0087] The enzyme activity unit U is defined as: the amount of enzyme required to produce 1 μmol of fatty acid per minute by lipase-catalyzed hydrolysis of olive oil at 37°C.
[0088] Where: X is lipase activity U / g; C is fatty acid concentration, μmol / mL; V is the volume of fatty acid, mL; m is the mass of lipase, g; t is the reaction time, min.
[0089] Drawing of the working curve of oleic acid absorbance: Prepare oleic acid solutions of different gradient concentrations and blank solutions without oleic acid. Take 4 mL of oleic acid solution and place it in a conical flask. Add 1 mL of copper acetate color developer and stir magnetically for 3 minutes. 2+A green complex is generated. After centrifugation, the upper organic phase and blank solution are taken and the absorbance is measured at 710 nm. The absorbance is plotted against the oleic acid concentration. Figure 2 This is the working curve of oleic acid absorbance.
[0090] Enzyme activity determination method: Weigh a certain mass of immobilized enzyme, take 3mL phosphate buffer solution (pH7.0) and 1mL olive oil, place in a conical flask, and react on a constant temperature shaking table at 37°C and 160rmin. After 10 minutes of reaction, add 6mL toluene to terminate the reaction, centrifuge the reaction solution at 1000rmin for 10 minutes, take 2mL supernatant and add 14mL toluene and 2mL copper acetate solution for color development, and then use a UV spectrophotometer to measure the absorbance value (710nm). Prepare a blank solution without lipase in the same way as a reference, and compare it with the oleic acid absorbance working curve to obtain the concentration of fatty acids.
[0091] The specific enzyme activity of the immobilized lipase was calculated to be 175.78 U / g.
[0092] Example 5: Construction of the initial reaction system for the synthesis of VC-IP using immobilized Beri-LP enzyme
[0093] Reaction system and material addition method:
[0094] 1. Co-substrate solution: 38.463 g 2-n-hexyldecanoic acid and 0.54 g anhydrous Na2SO4 were dissolved in 100 mL N,N-dimethylformamide solvent and stored at 4°C.
[0095] 2. Enzymatic reaction system: The reaction vessel is a 1000 mL three-necked flask, the total volume of the reaction liquid is 600 mL, the temperature is 40°C, and the stirring speed is 400 rpm / min.
[0096] 3. Control of reaction conditions and separation and purification: 5.2836g L-ascorbic acid, 400mL tert-butyl alcohol, and 100mL N,N-dimethylformamide were added to a 1000mL three-necked flask, and after stirring to dissolve, 24g (40g / L) immobilized Beri-LP enzyme was added. The reaction of 2-n-hexyldecanoic acid was started, and the flow rate was 20ml / L. The reaction was continued for 5 hours after the flow addition was completed. After the reaction was completed, the immobilized enzyme and the residual L-ascorbic acid were separated by filtration, and the filtrate was separated to remove the organic solvent. The obtained oily substance was washed 3 times with purified water, dried with Na2SO4, and filtered again to obtain a colorless oily substance, and an almost colorless or light yellow oily substance was obtained.
[0097] 2-n-Hexyldecanoic acid detection method: Instrument: HPLC-CAD (high performance liquid chromatograph-electrospray detector); Chromatographic conditions: Chromatographic column: Waters Acquity UPLC HSS T3, 2.1×100mm, 1.8μm; Column temperature: 40℃; Flow rate: 0.5mL / min; Injection volume: 5μL; Mobile phase A: 0.1% formic acid aqueous solution, mobile phase B: acetonitrile; Isocratic elution; Mobile phase A (%): mobile phase B (%) = 70:30, external standard method. The following liquid phase conditions are the same.
[0098] VC-IP detection method: Column C18, 250mm×4.6mm, 5μm; mobile phase: tetrahydrofuran: acetonitrile = 2:8; flow rate: 1.0mL / min; detection wavelength: 236nm; column temperature: 30℃; injection volume: 10μL, external standard method. The following liquid phase conditions are the same.
[0099] Liquid phase detection analysis showed that the substrate conversion rate was 73.4%, the VC-IP yield was 72.6%, the VC-IP yield was 85.2%, and the product purity was 93.7%.
[0100] The HPLC test results of 2-n-hexyldecanoic acid sampled during the reaction are as follows: Figure 3 After the reaction, the HPLC test results of VC-IP were as follows: Figure 4 shown.
[0101] Example 6: Optimization of reaction conditions for the synthesis of VC-IP using immobilized Beri-LP enzyme
[0102] The benchmark reaction system for optimized conditions is as follows:
[0103] 1. Co-substrate solution: 38.463 g 2-n-hexyldecanoic acid and 0.54 g anhydrous Na2SO4 were dissolved in 100 mL N,N-dimethylformamide solvent and stored at 4°C.
[0104] 2. Enzymatic reaction system: The reaction vessel is a 1000 mL three-necked flask, the total volume of the reaction liquid is 600 mL, the temperature is 40°C, and the stirring speed is 400 rpm / min.
[0105] 3. Control of reaction conditions and separation and purification: 5.2836g L-ascorbic acid, 400mL tert-butyl alcohol, and 100mL N,N-dimethylformamide were added to a 1000mL three-necked flask, and after stirring to dissolve, 24g immobilized Beri-LP enzyme was added. The reaction of 2-n-hexyldecanoic acid was started, and the flow rate was 20ml / L. The reaction was continued for 5 hours after the flow addition was completed. After the reaction was completed, the immobilized enzyme and the residual L-ascorbic acid were separated by filtration, and the filtrate was separated to remove the organic solvent. The obtained oil was washed with purified water 3 times, dried with Na2SO4, and filtered again to obtain a colorless oil, and an almost colorless or light yellow oil was obtained.
[0106] On the basis of keeping other conditions unchanged, a single factor test is conducted on a certain factor / condition to examine the catalytic effect (substrate conversion rate).
[0107] Optimization conditions 1: Effect of different reaction media on catalytic effect: acetone (logP = -0.24), tert-butyl alcohol (logP = 1.32), tert-amyl alcohol (logP = 1.15), petroleum ether (logP = 2.62), n-hexane (logP = 3.53). Figure 5 As shown, the best reaction medium is tert-butyl alcohol, followed by tert-amyl alcohol, petroleum ether and n-hexane.
[0108] Optimization condition 2: The flow rate of the co-substrate solution was investigated in the range of 5 mL / h to 60 mL / h. Figure 6 As shown, when the flow acceleration of 2-n-hexyldecanoic acid solution is 5-30 mL / h, its conversion rate is greater than 85%, and the optimal flow acceleration is 20 mL / h.
[0109] Optimization condition 3: In the temperature range of 25℃~65℃, the catalytic effect at different temperatures was investigated. Figure 7 As shown, the optimal enzymatic reaction temperature is 45℃~65℃.
[0110] Optimization condition 4: different molar ratios of substrate L-ascorbic acid and co-substrate 2-n-hexyldecanoic acid were investigated: 1:(4-12). Figure 8 As shown, the feed ratio of substrate to co-substrate is 1:(5-10), the conversion rate is greater than 80%, and the optimal feed ratio of substrate to co-substrate is 1:(5-8).
[0111] Example 7: Amplification of VC-IP synthesis by immobilized Beri-LP enzyme and product structure identification
[0112] The optimized reaction system is as follows: Expand the reaction system to 6L:
[0113] 1. Co-substrate solution: 384.63 g 2-n-hexyldecanoic acid and 5.4 g anhydrous Na2SO4 were dissolved in 1 L N,N-dimethylformamide solvent and stored at 4°C.
[0114] 2. Enzymatic reaction system: The reaction vessel is a 10L conversion tank, the total volume of the reaction liquid is 6L, the temperature is 40°C, and the stirring speed is 400rpm / min.
[0115] 3. Control of reaction conditions and separation and purification: 52.836g L-ascorbic acid, 4L tert-butyl alcohol, and 1L N,N-dimethylformamide were added to a 10L conversion tank, and after stirring and dissolving, 240g immobilized Beri-LP enzyme was added. The reaction of 2-n-hexyldecanoic acid was started, and the flow rate was 20ml / L. The reaction was continued for 5 hours after the flow addition was completed. After the reaction was completed, the immobilized enzyme and the residual L-ascorbic acid were separated by filtration, and the filtrate was separated to remove the organic solvent. The obtained oily substance was washed 3 times with purified water, dried with Na2SO4, and filtered again to obtain a colorless oily substance, and an almost colorless or light yellow oily substance was obtained.
[0116] The results showed that after 15 hours of reaction with 150 mM substrate, the conversion rate reached 99.35%, and 986.28 g of product was obtained after separation and purification.
[0117] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.
Claims
1. A lipase mutant, characterized in that: The amino acid sequence of the lipase mutant is shown in SEQ ID NO.
1.
2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the lipase mutant according to claim 1; the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID NO.
5.
3. A recombinant expression vector, characterized in that: The recombinant expression vector comprises a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO.
5.
4. A recombinant engineered bacterium, characterized in that: The recombinant engineered bacteria comprises a nucleic acid molecule with a nucleotide sequence as shown in SEQ ID NO.5 or a recombinant expression vector as described in claim 3.
5. The method for preparing the lipase mutant according to claim 1, characterized in that: The steps include: (1) cultivating the recombinant engineered bacteria according to claim 4; (2) Inducing the recombinant engineered bacteria to express a lipase mutant.
6. The preparation method according to claim 5, characterized in that: The steps include: (1) Introducing NdeI and XhoI sites at both ends of the nucleic acid molecule with a nucleotide sequence as shown in SEQ ID NO.5, respectively, and cloning it into a pET28a vector to obtain a recombinant vector; transforming the constructed recombinant vector into Escherichia coli BL21 (DE3) competent cells, coating it on an LB plate containing kanamycin resistance, and picking a single clone cell after culturing to obtain a recombinant engineered bacterium; (2) Inducing the expression of the recombinant engineered bacteria to obtain an enzyme solution containing the lipase mutant.
7. A method for synthesizing ascorbyl tetraisopalmitate, characterized in that: Ascorbyl tetraisopalmitate is synthesized by using the lipase mutant described in claim 1.
8. The synthesis method according to claim 7, characterized in that The method comprises the following steps: using ascorbic acid as a substrate, 2-n-hexyldecanoic acid as a co-substrate and an organic solvent as a reaction medium, reacting under the catalytic action of the lipase mutant of claim 1 to synthesize ascorbic acid tetraisopalmitate.
9. The synthesis method according to claim 8, characterized in that The final molar ratio of the ascorbic acid to the 2-n-hexyldecanoic acid is 1:(4-12).
10. The synthesis method according to claim 8, characterized in that The lipase mutant is added in the form of immobilized lipase, and the added amount of the immobilized lipase is 20-80 g / L.
11. The synthesis method according to claim 8, characterized in that The 2-n-hexyldecanoic acid is added by flow addition, and the flow addition speed is controlled to be 5-60 mL / L.
12. The synthesis method according to claim 8, characterized in that The organic solvent includes N,N-dimethylformamide.
13. The synthesis method according to claim 12, characterized in that: The organic solvent further comprises at least one of tert-butyl alcohol, tert-amyl alcohol, acetone, petroleum ether and n-hexane.
